In silico toxicology protocols

Glenn J. Myatt(LeadScope (United States)), Ernst Ahlberg(AstraZeneca (Sweden)), Yumi Akahori(Chemicals Evaluation and Research Institute), David Allen(Integrated Laboratory Systems, Inc.), Alexander Amberg(Sanofi (Germany)), Lennart T. Anger(Sanofi (Germany)), Aynur O. Aptula(Unilever (United Kingdom)), Scott S. Auerbach(National Institute of Environmental Health Sciences), Lisa Beilke, Phillip Bellion(DSM (Switzerland)), Romualdo Benigni, Joel P. Bercu(Gilead Sciences (United States)), Ewan D. Booth(Syngenta (United Kingdom)), Dave Bower(LeadScope (United States)), Alessandro Brigo(Roche (Switzerland)), Natalie Burden(National Centre for the Replacement Refinement and Reduction of Animals in Research), Zoryana Cammerer(Janssen (United States)), M Cronin(Liverpool John Moores University), Kevin P. Cross(LeadScope (United States)), Laura Custer(Bristol-Myers Squibb (United States)), Magdalena Dettwiler(Swiss Archaeology), Krista L. Dobo(Pfizer (United States)), Kevin A. Ford(LeadScope (United States)), Marie Fortin(Rutgers, The State University of New Jersey), Samantha Gad-McDonald(Gad Consulting Services (United States)), Nichola Gellatly(National Centre for the Replacement Refinement and Reduction of Animals in Research), Véronique Gervais(Bristol-Myers Squibb (Netherlands)), Kyle Glover(Defense Threat Reduction Agency), Susanne Glowienke(Novartis (Switzerland)), Jacky Van Gompel(Johnson & Johnson (United States)), Steve Gutsell(Unilever (United Kingdom)), Barry Hardy(Unilever (United Kingdom)), James Harvey(GlaxoSmithKline (United Kingdom)), Jedd Hillegass(Bristol-Myers Squibb (Germany)), Masamitsu Honma(National Institute of Health Sciences), Jui-Hua Hsieh(Kelly Services (United States)), Chia-Wen Hsu(Center for Drug Evaluation and Research), Kathy Hughes(Health Canada), Candice Johnson(LeadScope (United States)), Robert A. Jolly(Eli Lilly (United States)), Davey L. Jones(Integrated Laboratory Systems, Inc.), Ray Kemper(Bristol-Myers Squibb (Netherlands)), Michelle Kenyon(Pfizer (United States)), Marlene T. Kim(Center for Drug Evaluation and Research), Naomi L. Kruhlak(Center for Drug Evaluation and Research), Sunil Kulkarni(Health Canada), Klaus Kümmerer(Leuphana University of Lüneburg), Penny Leavitt(Bristol-Myers Squibb (Germany)), Bernhard Majer(Bristol-Myers Squibb (Netherlands)), Scott A. Masten(National Institute of Environmental Health Sciences), Scott A. Miller(National Institute of Environmental Health Sciences), Janet Moser(Battelle), Moiz Mumtaz(Agency for Toxic Substances and Disease Registry), Wolfgang Muster(Roche (Switzerland)), Louise Neilson(British American Tobacco (United Kingdom)), Tudor I. Oprea(University of New Mexico), Grace Patlewicz(Environmental Protection Agency), Alexandre Tadeu Paulino(Bristol-Myers Squibb (Netherlands)), Elena Lo Piparo(Bristol-Myers Squibb (Netherlands)), Mark W. Powley(Center for Drug Evaluation and Research), Donald P. Quigley(LeadScope (United States)), M. Vijayaraj Reddy(United States Military Academy), Andrea-Nicole Richarz(European Commission), Patricia Ruiz(Agency for Toxic Substances and Disease Registry), Benoı̂t Schilter(Nestlé (Switzerland)), Rositsa Serafimova(European Food Safety Authority), Wendy Simpson(Unilever (United Kingdom)), Lidiya Stavitskaya(Center for Drug Evaluation and Research), Reinhard Stidl(Bristol-Myers Squibb (Netherlands)), Diana Suarez-Rodriguez(Unilever (United Kingdom)), David T. Szabo(Unilever (United Kingdom)), Andrew Teasdale(AstraZeneca (United Kingdom)), Alejandra Trejo‐Martin(Gilead Sciences (United States)), Jean‐Pierre Valentin(Bristol-Myers Squibb (Netherlands)), Anna Vuorinen(DSM (Switzerland)), B. Wall(Colgate-Palmolive (United States)), Pete Watts(Bibra International), Angela White(GlaxoSmithKline (United Kingdom)), Joerg Wichard(GlaxoSmithKline (United Kingdom)), Kristine L. Witt(GlaxoSmithKline (United Kingdom)), Adam Woolley(National One Call (United Kingdom)), David Woolley(National One Call (United Kingdom)), Craig Zwickl(National Institute of Health Sciences), Catrin Hasselgren(LeadScope (United States))
Regulatory Toxicology and Pharmacology
April 17, 2018
Cited by 239Open Access
Full Text

Abstract

The present publication surveys several applications of in silico (i.e., computational) toxicology approaches across different industries and institutions. It highlights the need to develop standardized protocols when conducting toxicity-related predictions. This contribution articulates the information needed for protocols to support in silico predictions for major toxicological endpoints of concern (e.g., genetic toxicity, carcinogenicity, acute toxicity, reproductive toxicity, developmental toxicity) across several industries and regulatory bodies. Such novel in silico toxicology (IST) protocols, when fully developed and implemented, will ensure in silico toxicological assessments are performed and evaluated in a consistent, reproducible, and well-documented manner across industries and regulatory bodies to support wider uptake and acceptance of the approaches. The development of IST protocols is an initiative developed through a collaboration among an international consortium to reflect the state-of-the-art in in silico toxicology for hazard identification and characterization. A general outline for describing the development of such protocols is included and it is based on in silico predictions and/or available experimental data for a defined series of relevant toxicological effects or mechanisms. The publication presents a novel approach for determining the reliability of in silico predictions alongside experimental data. In addition, we discuss how to determine the level of confidence in the assessment based on the relevance and reliability of the information.


Related Papers